Fig. 8
Enhanced dysfunction of MAPKs and PI3K/AKT pathways. a Dose-dependent dysfunction of MAPKs pathway. b Dose-dependent dysfunction of PI3K/AKT pathway. c Effect of U0126 (ERK inhibitor) on p-ERK expression in Ru@SiO2-PA-treated cells. d Effect of LY294002 (AKT inhibitor) on p-AKT expression in Ru@SiO2-PA-treated cells. e Effects of four inhibitors on Ru@SiO2-PA-treated cells viability. SGC-7901 cells were pre-treated with inhibitors for 2 h or/and co-treated with 2.5–10 μg/ml Ru@SiO2 or Ru@SiO2-PA for 72 h. Protein expression was examined by western blot analysis. Cells viability was detected by MTT assay. Bars with different letters indicate the P < 0.05 level